These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28210006)

  • 1. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
    Sugino N; Kawahara M; Tatsumi G; Kanai A; Matsui H; Yamamoto R; Nagai Y; Fujii S; Shimazu Y; Hishizawa M; Inaba T; Andoh A; Suzuki T; Takaori-Kondo A
    Leukemia; 2017 Nov; 31(11):2303-2314. PubMed ID: 28210006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia.
    Tatsumi G; Kawahara M; Yamamoto R; Hishizawa M; Kito K; Suzuki T; Takaori-Kondo A; Andoh A
    Leukemia; 2020 Mar; 34(3):746-758. PubMed ID: 31676828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective dissociation between LSD1 and GFI1B by a LSD1 inhibitor NCD38 induces the activation of
    Yamamoto R; Kawahara M; Ito S; Satoh J; Tatsumi G; Hishizawa M; Suzuki T; Andoh A
    Oncotarget; 2018 Apr; 9(30):21007-21021. PubMed ID: 29765516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
    Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
    Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
    Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
    Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
    Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
    Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.
    Benetatos L; Vartholomatos G
    Cell Mol Life Sci; 2018 Jun; 75(11):1999-2009. PubMed ID: 29484447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
    Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
    Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts.
    Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Monaldi D; Ruoppolo G; Tilset M; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A
    Eur J Med Chem; 2015 Apr; 94():163-74. PubMed ID: 25768700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML.
    Nicosia L; Boffo FL; Ceccacci E; Conforti F; Pallavicini I; Bedin F; Ravasio R; Massignani E; Somervaille TCP; Minucci S; Bonaldi T
    Oncogene; 2022 Feb; 41(6):878-894. PubMed ID: 34862459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
    Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
    Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
    Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
    Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
    Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
    Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia.
    Magliulo D; Bernardi R; Messina S
    Front Oncol; 2018; 8():255. PubMed ID: 30073149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Region-specific alteration of histone modification by LSD1 inhibitor conjugated with pyrrole-imidazole polyamide.
    Alagarswamy K; Shinohara KI; Takayanagi S; Fukuyo M; Okabe A; Rahmutulla B; Yoda N; Qin R; Shiga N; Sugiura M; Sato H; Kita K; Suzuki T; Nemoto T; Kaneda A
    Oncotarget; 2018 Jun; 9(50):29316-29335. PubMed ID: 30034620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.